Sartorius AG

Sartorius AG shares rose over 11% following strong Q3 results that exceeded expectations, prompting an upward revision of the company's 2025 forecast. The biotech segment, Sartorius Stedim Biotech, reported a 12% growth at constant exchange rates, contributing to an overall 10.6% growth for the quarter. The company now anticipates 9% revenue growth for the full year and has raised its EBITDA margin target to 31%. The positive market reaction reflects confidence in Sartorius's fundamentals and growth potential in the biotech sector.

Stock Invest

Sartorius AG Shares Jump 11% After Surpassing Q3 Expectations and Lifting 2025 Forecast

Sartorius AG reported a 7.5% sales growth for the first nine months of 2025, with group sales revenue reaching €2.92 billion. The Bioprocess Solutions division grew by approximately 10%, while the Lab Products & Services division showed recovery. EBIT increased to €399.0 million, and net profit rose to €186.4 million. The operating earnings margin improved to 29.7%. However, cash flow from financing activities decreased significantly, and cash and cash equivalents fell to €389.9 million.

Reuters

Sartorius AG Reports 7.5% Sales Growth and Higher Earnings for First Nine Months of 2025

SARTORIUS AG :SHARPENS GUIDANCE AFTER SIGNIFICANTLY PROFITABLE SALES REVENUE GROWTH IN THE FIRST NINE MONTHSREPORTS 7.5% SALES REVENUE GROWTH IN FIRST NINE MONTHSUNDERLYING EBITDA UP 13%, MARGIN AT 29.7%EXPECTS 7% SALES GROWTH, EBITDA MARGIN ABOVE 29.5%9M UNDERLYING NET PROFIT UP 17% TO 244 MILLION EUROS9-MONTH SALES REVENUE 2.6 BILLION EUROFY OUTLOOK: SALES REVENUE GROWTH AT GROUP LEVEL OF AROUND 7 PERCENT (PREVIOUSLY: AROUND 6 PERCENT) FY OUTLOOK: UNDERLYING EBITDA MARGIN AT GROUP LEVEL OF SLIGHTLY ABOVE 29.5 PERCENT (PREVIOUSLY: AROUND 29 TO 30 PERCENT)

Sartorius Sharpens Guidance After 9M Sales Revenue Growth

European shares fell on Tuesday due to disappointing earnings and trade deal anxieties, with the pan-European STOXX 600 down 0.4%. The EU is reportedly preparing retaliatory measures against U.S. tariffs, while the U.K. budget deficit widened significantly. Notable declines included Akzo Nobel NV (-3%), Givaudan (-5.4%), and Sartorius AG (-7.3%). In contrast, Integrum AB shares surged 110% following a takeover offer recommendation. Overall, market sentiment remains cautious amid ongoing trade tensions and economic concerns.

rttnews

European Shares Decline On Trade Deal Anxiety

SARTORIUS AG :GROUP SALES REVENUE UP 6.1 PERCENT IN FIRST SIX MONTHSUNDERLYING EBITDA ROSE SIGNIFICANTLY BY 11.9 PERCENT TO 527 MILLION EUROS IN FIRST HALF OF YEARUNDERLYING NET PROFIT GREW EVEN MORE STRONGLY, UP BY 13.7 PERCENT TO 169 MILLION EUROS, COMPARED WITH 148 MILLION EUROS IN SAME PERIOD OF LAST YEARGUIDANCE FOR 2025 CONFIRMEDSALES REVENUE AND MARGIN FORECAST DOES NOT INCLUDE POSSIBLE EFFECTS OF TARIFFS OR RELATED MITIGATING AND CORRECTIVE MEASURESMANAGEMENT DOES NOT EXPECT ANY INFLUENCE ON STRONG MARKET POSITION AND COMPETITIVENESS OF SARTORIUS

Sartorius H1 Underlying EBITDA Up At EUR 527 Mln

Sartorius AG reported a 6.1% increase in group sales revenue for H1 2025, totaling €1.767 billion, with the Bioprocess Solutions Division growing by 8.8%. Underlying net profit rose by 13.7% to €169 million, and EPS increased to €2.44. The company maintains its 2025 guidance, expecting around 6% organic sales growth and an EBITDA margin of 29-30%.

Sartorius AG Reports 6.1% Increase in Group Sales Revenue and 13.7% Rise in Underlying Net Profit for H1 2025; EPS Grows to €2.44

Sartorius AG announced the transfer of 7,741 ordinary shares to Dr. Michael Große as part of a share-based remuneration component, fulfilling a grant made prior to his Management Board mandate. This transaction was disclosed on July 4, 2025, and took place outside a trading venue on July 2, 2025. Dr. Große is a member of the managing body of Sartorius AG, which is responsible for the announcement's content.

Sartorius AG: Dr.  Michael Große, Transfer of 7,741 ordinary shares as a share-based remuneration component in fulfillment of a grant made before the start of the Management Board mandate.

The pharmaceutical membrane filters market is projected to exceed USD 20.05 billion by 2031, growing at a CAGR of 13.1%. This growth is driven by rising demand for biopharmaceuticals and stringent regulatory requirements for drug safety. Key segments include microfiltration and hollow fiber systems, with North America leading the market. Major players include Sartorius AG and Parker Hannifin Corporation. The market is evolving with trends in single-use technologies and sustainability, positioning membrane filtration as essential for product purity and process efficiency.

prnewswire

Parker Hannifin

10:50 ET
			
			
				Pharmaceutical Membrane Filters Market Size to Surpass USD 20.05 Billion by 2031, at 13.1% CAGR: The Insight Partners

The global medical bioreactor market is projected to grow from $4.1 billion in 2024 to $7.2 billion by 2034, with a CAGR of 6.2%. Key growth drivers include increased biopharmaceutical production, advancements in regenerative medicine, and rising biotech investments. North America leads the market, while Asia-Pacific is expected to experience the fastest growth. Major players include Sartorius AG, Thermo Fisher Scientific, and GE Healthcare. Challenges such as high costs and operational complexity may impact growth.

Unusual Whales

Thermo Fisher Scentific

Global medical bioreactor market valued at $4.1 billion in 2024, projected to reach $7.2 billion by 2034, with a CAGR of 6.2%. Major drivers include biopharmaceutical production, regenerative medicine advancements, growing biotech investments. North America leads, Asia-Pacific shows fastest growth. Major players include Sartorius AG, Thermo Fisher Scientific, GE Healthcare.

Sartorius AG (SARTF) reported strong Q1 results with a revenue increase of 7.7% to €883 million and a non-GAAP EPS of €1.23. The company's net operating cash flow tripled to €139 million, indicating improved operational efficiency. Additionally, the net debt to EBITDA ratio decreased to 3.9, and the EBITDA margin rose to 29.8%, showcasing robust financial health and profitability improvements.

GuruFocus

Sartorius AG (SARTF) Reports Strong Q1 Growth and Financial Improvements

April 16 (Reuters) - Sartorius AG (SATG.DE) :* SARTORIUS CEO: WITH A VIEW TO U.S. TARIFFS, WE ARE WELL PLACED THANKS TO OUR GLOBAL NETWORK* SARTORIUS CEO: WE ARE CERTAIN TO EXPAND OUR PRODUCTIONS IN CHINA LOCALLY Source text: Further company coverage: (SATG.DE)((frankfurt.newsroom@thomsonreuters.com;))

Sartorius CEO: Certain To Expand Our Production In China Locally

The Medical Filtration Market is expected to reach $9.35 billion by 2030, growing at a CAGR of 6.8%. Growth is driven by regulatory frameworks, demand for high-quality solutions, and technological advancements. PES material dominates the market, while nanofiltration is the fastest-growing technology. Major players include Merck KGaA, 3M, Danaher, Sartorius AG, Veolia, and Thermo Fisher Scientific. North America is a key market, facing challenges like high costs and filter disposal.

Danaher

Merck KGaA

Medical Filtration Market projected to reach $9.35 billion by 2030, at 6.8% CAGR, driven by demand for high-quality solutions and technological advancements. PES material leads the market, with nanofiltration as the fastest growing technology. Key players include Merck KGaA, 3M, Danaher, Sartorius AG, Veolia, Thermo Fisher Scientific Inc, and more.

Barclays has upgraded Sartorius AG and its subsidiary Sartorius Stedim Biotech SA to Overweight, citing a post-COVID recovery in the bioprocessing industry. The firm notes both stocks are undervalued compared to peers, with potential for upside as order momentum returns. Barclays forecasts 12% order growth for Sartorius in FY25 and has raised price targets for both stocks. The report highlights a significant increase in free cash flow and expects leverage to decline by FY26, indicating a positive outlook for earnings estimates and investor interest.

Investing

Barclays

Sartorius AG and its biotech subsidiary lifted to Buy at Barclays

Securities analysts have revised ratings and price targets for several European companies, including BASF, Sartorius, and Yubico. Citigroup reinstated coverage of BASF with a neutral rating and a price target of EUR 51. Barclays upgraded Sartorius to overweight and raised its target price to EUR 320. Berenberg upgraded Yubico to buy but lowered its target price to SEK 270. Other companies also saw target price adjustments from various analysts, reflecting a mix of upgrades and downgrades across the sector.